ALX Oncology Holdings Inc. (ALXO)
After hours:
| Previous Close | 2.1400 |
| Open | 2.1600 |
| Bid | 2.2000 x 200 |
| Ask | 2.2500 x 100 |
| Day's Range | 2.1550 - 2.2200 |
| 52 Week Range | 1.8800 - 17.8250 |
| Volume | |
| Avg. Volume | 1,314,708 |
| Market Cap | 116.931M |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6400 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.33 |
GlobeNewswireALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today that management will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 17 – 19, 2024. Format: Fireside chat with analyst, Li Watsek and 1x1 meetingsDate: Tuesday, September 17, 2024 Tim
- GlobeNewswire
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myelomaSOUTH SAN FRANCISCO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced the first patients have been dosed in an arm of the randomized UMBRELLA phase 1/2 clin
- GlobeNewswire
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. “Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications,” said Jas
